QUEST DIAGNOSTICS INC
Government Contracts & Awards
Q301--VISN22 | REFERENCE LABORATORY TESTING
$30,939,867VISN 7 REF LAB BRIDGE 5 MONTH +2 MONTH OPT
$6,574,968Proprietary Tech & Patents
No patents found in our USPTO sample (a narrow, keyword-clustered feed of recent grants in strategic tech sectors — not a comprehensive patent database).
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
Apple Health app Users to be Able to Order Labs from Quest Diagnostics
Quest Diagnostics (NYSE: DGX) today announced that Apple Health app users in the United States1 will be able to conveniently purchase a tailored Quest laboratory test panel that includes over 50 biomarkers directly through the app on iPhone and iPad later this year. Apple first announced the upcoming update today at its September event.
Quest Diagnostics CEO Sells 10,000 Shares for $2.4 Million
J. E. Davis disposed of 8% of his direct equity stake under a pre-planned Rule 10b5-1 trading arrangement, retaining $28.9 million in company stock.
UBS Maintains Neutral on Quest Diagnostics, Raises Price Target to $245
UBS analyst Kevin Caliendo maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $232 to $245.
Quest Diagnostics (NYSE:DGX) Shows Dividend Quality Beyond the Headline Yield
Quest Diagnostics (DGX) passes Best Dividend screen: dividend rating 7, profitability 7, health 6. Yield 1.46% with sustainable payout.
Quest Diagnostics Declares Quarterly Cash Dividend
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.86 per share, payable on October 21, 2026 to shareholders of record of Quest Diagnostics common stock on October 6, 2026.
Quest Diagnostics Raises 2026 Outlook as Testing Demand Accelerates
DGX raised its 2026 outlook as testing demand surged, but lower-margin deals and rising project costs could temper the payoff.
Is DGX Stock Worth Buying After Its Strong 2026 Earnings Momentum?
Quest Diagnostics' earnings beat, raised 2026 outlook and broad testing demand support momentum, but valuation, debt and margin pressure temper the buy case.
Quest Diagnostics Growth Drivers Investors Should Watch Now in 2026
DGX's broad testing demand, payer access, advanced diagnostics and partnerships support 2026 growth as AI and automation target costs.
Quest Diagnostics Incorporated (DGX) Soars to 52-Week High, Time to Cash Out?
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $250
Barclays analyst Luke Sergott maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $230 to $250.
Congressional Trades in $DGX
Insider Trades (Form 4)
WENTWORTH TIMOTHY C
Davis J. E.
PREVOZNIK MICHAEL E
DELANEY MARK E
Gregg Vicky B
Plewman Patrick
MAIN TIMOTHY L
CARTER ROBERT B
Key People
Davis J E
CEO and President
PREVOZNIK MICHAEL E
SVP & General Counsel
Plewman Patrick
SVP for Diagnostic Services
DELANEY MARK E
SVP & Chief Commercial Officer
KUPPUSAMY KARTHIK
SVP, Clinical Solutions
Lassiter Wright
Director
CARTER ROBERT B
Director
SAMAD SAM
Executive Vice President & CFO
WENTWORTH TIMOTHY C
Director
Doi Tracey
Director
MAIN TIMOTHY L
Director
Gregg Vicky B
Director
Diaz Luis
Director
Political Giving
$155,500 given to 39 candidates across 76 disclosed contributions (FEC Schedule A).
Scott H. Peters
Lori Trahan
Frank Pallone
Nanette Barragan
Kim Schrier
Darin McKay LaHood
Gus Bilirakis
Kathy Castor
Bill Cassidy
Ron Wyden
John Cornyn
Gus M. Bilirakis
Terri A. Sewell
Ashley Moody
Mitch McConnell
Elizabeth Fletcher
Markwayne Mullin
Lloyd K. Smucker
Daniel Crenshaw
Laurel Lee
+ 19 more recipients not shown.
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro